Remdesivir, on the road to DisCoVeRy
- PMID: 34534513
- PMCID: PMC8439616
- DOI: 10.1016/S1473-3099(21)00559-4
Remdesivir, on the road to DisCoVeRy
Conflict of interest statement
We declare no competing interests.
Comment in
-
Clindamycin-resistant Streptococcus pyogenes in Chinese children.Lancet Infect Dis. 2021 Dec;21(12):1631-1632. doi: 10.1016/S1473-3099(21)00699-X. Lancet Infect Dis. 2021. PMID: 34838224 Free PMC article. No abstract available.
Comment on
-
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14. Lancet Infect Dis. 2022. PMID: 34534511 Free PMC article. Clinical Trial.
References
-
- Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00485-0. published online Sept 14. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
